v3.22.2.2
Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Oct. 02, 2022
Oct. 03, 2021
Oct. 02, 2022
Oct. 03, 2021
Revenue from External Customer [Line Items]        
Revenues [1] $ 22,638 $ 24,035 $ 76,040 $ 57,450
Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues [1],[2] 22,319 23,513 75,066 56,101
PC1 [Member]        
Revenue from External Customer [Line Items]        
Revenues [2] 319 521 974 1,348
Total Alliance revenues [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,689 2,068 6,320 5,718
Primary Care [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 15,846 16,680 55,676 35,804
Primary Care [Member] | Comirnaty direct sales and alliance revenues [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues [3] 4,402 12,977 26,477 24,277
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 7,514 0 17,099 0
Primary Care [Member] | Eliquis alliance revenues and direct sales [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,464 1,346 5,001 4,470
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 1,607 1,447 4,601 3,971
Primary Care [Member] | Premarin family [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 110 148 327 420
Primary Care [Member] | Nimenrix [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 79 51 221 145
Primary Care [Member] | BMP2 [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 58 71 201 186
Primary Care [Member] | FSME/IMMUN-TicoVac [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 67 47 177 161
Primary Care [Member] | Toviaz [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 30 56 130 174
Primary Care [Member] | Trumenba [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 60 52 108 102
Primary Care [Member] | Chantix / Champix [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 4 7 8 409
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 451 479 1,326 1,490
Specialty Care [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 3,404 3,749 10,267 11,205
Specialty Care [Member] | Vyndaqel/Vyndamax [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 602 501 1,766 1,454
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 502 610 1,304 1,734
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 230 283 767 888
Specialty Care [Member] | Sulperazon [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 178 181 598 515
Specialty Care [Member] | Inflectra [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 131 172 403 485
Specialty Care [Member] | Ig Portfolio Products [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues [5] 124 99 356 311
Specialty Care [Member] | BeneFIX [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 99 104 325 328
Specialty Care [Member] | Zavicefta [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 98 107 302 306
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 90 95 261 284
Specialty Care [Member] | Zithromax [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 71 66 250 198
Specialty Care [Member] | Medrol [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 79 109 235 320
Specialty Care [Member] | Fragmin [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 60 74 202 223
Specialty Care [Member] | Somavert [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 70 70 202 203
Specialty Care [Member] | ReFacto AF/Xyntha [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 58 69 188 235
Specialty Care [Member] | Vfend [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 51 51 171 204
Specialty Care [Member] | All other Anti-infectives [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 374 455 1,123 1,384
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 586 702 1,816 2,134
Oncology [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 3,070 3,085 9,124 9,091
Oncology [Member] | Ibrance [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,283 1,381 3,841 4,039
Oncology [Member] | Xtandi alliance revenues [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 320 309 878 879
Oncology [Member] | Inlyta [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 252 256 760 742
Oncology [Member] | Zirabev [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 146 96 432 311
Oncology [Member] | Bosulif [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 141 136 425 395
Oncology [Member] | Xalkori [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 118 116 362 371
Oncology [Member] | Ruxience [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 120 124 357 343
Oncology [Member] | Retacrit [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 87 110 308 322
Oncology [Member] | Sutent [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 75 142 287 537
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 99 67 247 193
Oncology [Member] | Bavencio Alliance Revenues [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 73 54 198 122
Oncology [Member] | Aromasin [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 66 56 187 159
Oncology [Member] | Besponsa [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 55 50 164 145
Oncology [Member] | Braftovi [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues [6] 58 47 156 136
Oncology [Member] | Trazimera [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 51 45 149 131
Oncology [Member] | Mektovi [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 45 41 129 112
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues $ 80 $ 53 $ 243 $ 155
[1] On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See Note 1A.
[2] See Note 1A for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($7 million and $108 million for the third quarter and the first nine months of 2022, respectively, and $187 million and $274 million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio.
[3] Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization.
[4] Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult).
[5] Immunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig.
[6] Erbitux® is a registered trademark of ImClone LLC.